Skip to content
    Clinical Trials

    Sitagliptin Combined With Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer

    Yu et alSignal Transduction and Targeted Therapy

    Sitagliptin Combined With Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer
    Gemcitabine resistance presents a substantial therapeutic hurdle in pancreatic ductal adenocarcinoma (PDAC), where median survival for advanced disease remains near one year. Utilizing artificial intelligence-guided structure-based drug repurposing, investigators identified the DPP-4 inhibitor sitagliptin as a candidate ribonucleotide reductase (RRM1/2) inhibitor to sensitize PDAC to gemcitabine. Molecular dynamics simulations suggested that sitagliptin disrupts gemcitabine-RRM1/2 interactions, downregulating RRM1/2 expression and restoring chemosensitivity across PDAC cell lines, patient-derived organoids, and murine models, while enhancing the anti-tumor efficacy of both gemcitabine-nab-paclitaxel (GnP) and FOLFIRINOX regimens in preclinical testing.
    These findings led to the single-center phase 2 SITGEM-CARE trial (NCT05947825), which enrolled 22 patients with locally advanced or metastatic PDAC. Patient characteristics included a median age of 65.0 years, ECOG performance status 1 in 86.4%, Stage IV disease in 68.2%, and liver metastases in 54.5%. Participants received continuous daily oral sitagliptin at 100 mg alongside gemcitabine (1000 mg/m²) and nab-paclitaxel (125 mg/m²) administered on days 1 and 8 of 21-day cycles.
    Among the 22 evaluable patients, eight attained a partial response and 11 exhibited stable disease, resulting in an objective response rate of 36.4% (95% CI: 17.2–59.3%) and a disease control rate of 86.4% (95% CI: 65.1–97.1%). Over a median follow-up duration of 9.9 months, median progression-free survival was 6.6 months (95% CI: 4.8–12.4), with 6-month and 9-month PFS rates of 63.6% and 43.5%, respectively. Median overall survival was 12.5 months (95% CI: 7.8–not reached), and 62.9% of patients remained alive at 12 months. The combination was well tolerated with no Grade 4 or Grade 5 treatment-related adverse events. The authors note these findings are hypothesis-generating and warrant confirmation in adequately powered randomized clinical trials.

    Key Takeaways

    • In 22 evaluable patients with locally advanced or metastatic pancreatic ductal adenocarcinoma, sitagliptin plus gemcitabine and nab-paclitaxel yielded an objective response rate of 36.4% (95% CI: 17.2–59.3%) and a disease control rate of 86.4% (95% CI: 65.1–97.1%), with tumor shrinkage in 86.4% of patients.
    • At a median follow-up of 9.9 months, median progression-free survival reached 6.6 months (95% CI: 4.8–12.4) and median overall survival reached 12.5 months (95% CI: 7.8–not reached), with 62.9% of patients alive at 12 months.
    • The investigational combination regimen was well tolerated, with no Grade 4 or 5 treatment-related adverse events reported.
    Read the original sourceSignal Transduction and Targeted Therapy